Legal & General Group
RPTX

Legal & General Group’s Repare Therapeutics RPTX Stock Holding History

Legal & General Group’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-706
Closed -$5.15K – 3371
2023
Q4 		$5.15K Sell
706
-12,030
-94% -$67.3K ﹤0.01% 3324
2023
Q3 		$154K Hold
12,736
– – ﹤0.01% 2769
2023
Q2 		$135K Buy
12,736
+7,526
+144% +$77.5K ﹤0.01% 2806
2023
Q1 		$51.3K Buy
5,210
+577
+12% +$6.62K ﹤0.01% 2871
2022
Q4 		$68.2K Hold
4,633
– – ﹤0.01% 2893
2022
Q3 		$57K Hold
4,633
– – ﹤0.01% 2948
2022
Q2 		$65K Buy
4,633
+710
+18% +$8.36K ﹤0.01% 2953
2022
Q1 		$56K Hold
3,923
– – ﹤0.01% 2987
2021
Q4 		$83K Buy
3,923
+1,400
+55% +$33K ﹤0.01% 2948
2021
Q3 		$67K Buy
2,523
+1,817
+257% +$58.7K ﹤0.01% 2913
2021
Q2 		$22K Hold
706
– – ﹤0.01% 3263
2021
Q1 		$22K Buy
+706
New +$24K ﹤0.01% 3101
2020
Q3 		– Sell
-500
Closed -$16K – 3445
2020
Q2 		$16K Buy
+500
New +$16.1K ﹤0.01% 3160

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Legal & General Group's RPTX Position: Q1 2024 in Review

Legal & General Group sold out of Repare Therapeutics (RPTX) in Q1 2024, closing a stake of 706 shares — an estimated $5.15K sold.

Legal & General Group first reported a position in RPTX in Q2 2020 and held it in 13 quarters. The position peaked at $154K in Q3 2023. 71 funds tracked by Wall St. Rank hold RPTX as of Q1 2024.

  • Legal & General Group reported no remaining Repare Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Legal & General Group sold 706 Repare Therapeutics shares in Q1 2024, an estimated $5.15K.
  • Legal & General Group first reported a position in Repare Therapeutics in Q2 2020 and held it in 13 quarters.
  • Legal & General Group's Repare Therapeutics position peaked at $154K in Q3 2023.
  • 71 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2024.

Based on Legal & General Group's 13F filing for Q1 2024, filed 14 May 2024.